Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nebicapone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT known ✓ | P21964 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 7/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nebicapone SCHEMBL29379610 | 1.00 | TTR (0.56) | TTRGPR35KDM4EMEN1GMNN | |
| SCHEMBL7198182 | 0.92 | CRHBP (0.52) | TTRGPR35KDM4EMEN1GMNN | |
| SCHEMBL7048659 | 0.89 | TTR (0.52) | TTRGPR35KDM4EMEN1GMNN | |
| SCHEMBL7046444 | 0.89 | TTR (0.51) | TTRGPR35KDM4EMEN1GMNN | |
| SCHEMBL7046543 | 0.86 | TTR (0.58) | TTRGPR35KDM4EMEN1GMNN | |
| SCHEMBL7045653 | 0.86 | TTR (0.67) | TTRGPR35KDM4EMEN1GMNN | |
| SCHEMBL7046492 | 0.85 | TTR (0.55) | TTRGPR35KDM4EMEN1GMNN | |
| SCHEMBL7046913 | 0.85 | TTR (0.50) | TTRGPR35KDM4EMEN1GMNN | |
| SCHEMBL17506499 | 0.84 | TTR (0.54) | TTRGPR35KDM4EMEN1GMNN | |
| SCHEMBL7046690 | 0.84 | TTR (0.54) | TTRGPR35KDM4EMEN1GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1010688-B1 | Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | PORTELA & CA SA (PT) | 2003-04-09 | — | — | EP | claimed |
| US-6512136-B1 | Hypotensive, antiedemic agents; gastrointestinal disorders; Parkinson*s disease treatment | PORTELA & C.A., S.A. (PT) | 2003-01-28 | — | — | US | claimed |
| EP-1010688-A1 | Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | Portela & Ca., S.A. (PT) | 2000-06-21 | — | — | EP | claimed |
| US-12521363-B2 | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease | ORION CORPORATION (FI) | 2026-01-13 | — | — | US | disclosed |
| EP-3390351-B1 | NOVEL BICYCLIC-COMPOUNDS FOR USE AS A MEDICAMENT, IN PARTICULAR FOR TREATMENT OF PARKINSON'S DISEASE | KOESTER HUBERT (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20240050394-A1 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | ORION CORP (FI) | 2024-02-15 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11771675-B2 | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease | ORION CORPORATION (FI) | 2023-10-03 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-1010688-B1 | Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | PORTELA & CA SA (PT) | 2003-04-09 | — | — | EP | disclosed |
| EP-1010688-B1 | Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | PORTELA & CA SA (PT) | 2003-04-09 | — | — | EP | disclosed |
| JP-2003055214-A | 2-PHENYL-1-(3,4-DIHYDROXY-5-NITROPHENYL)-1-ETHANONE- SUBSTITUTED COMPOUND, METHOD FOR USING THE SAME IN TREATING CENTRAL AND PERIPHERAL NERVOUS DISORDER, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | PORTELA & CO SA | 2003-02-26 | — | — | JP | disclosed |
| US-6512136-B1 | Hypotensive, antiedemic agents; gastrointestinal disorders; Parkinson*s disease treatment | PORTELA & C.A., S.A. (PT) | 2003-01-28 | — | — | US | disclosed |
| US-6512136-B1 | Hypotensive, antiedemic agents; gastrointestinal disorders; Parkinson*s disease treatment | PORTELA & C.A., S.A. (PT) | 2003-01-28 | — | — | US | disclosed |
| CN-1296471-A | Substituted 2-phenyl-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system and pharmaceutical compositions containing them | PORTELA & CA SA (PT) | 2001-05-23 | — | — | CN | disclosed |
| WO-2000037423-A1 | SUBSTITUTED 2-PHENYL-1-(3,4-DIHYDROXY-5-NITROPHENYL)-1-ETHANONES, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PORTELA & C.A., S.A. (PT) | 2000-06-29 | — | — | WO | disclosed |
| EP-1010688-A1 | Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | Portela & Ca., S.A. (PT) | 2000-06-21 | — | — | EP | disclosed |
| EP-1010688-A1 | Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | Portela & Ca., S.A. (PT) | 2000-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | COMT 1685/4885TTR 872/4885GPR35 535/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | COMT 936/4885TTR 42/4885GPR35 354/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | COMT 1672/4885TTR 845/4885GPR35 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.